The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

J.P. Issa

Department of Leukemia and Experimental Therapeutics

The University of Texas M.D. Anderson Cancer Center


TX 77030



Name/email consistency: high



  • Department of Leukemia and Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. 2005 - 2010
  • University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. 2001 - 2008
  • Section of Translational Research, Department of Leukemia at the MD Anderson Cancer Center, University of Texas, Houston 77030, USA. 2005


  1. Epigenetic changes in the myelodysplastic syndrome. Issa, J.P. Hematol. Oncol. Clin. North Am. (2010) [Pubmed]
  2. Colon cancer: it's CIN or CIMP. Issa, J.P. Clin. Cancer Res. (2008) [Pubmed]
  3. Cancer prevention: epigenetics steps up to the plate. Issa, J.P. Cancer. Prev. Res. (Phila. Pa) (2008) [Pubmed]
  4. DNA methylation as a therapeutic target in cancer. Issa, J.P. Clin. Cancer Res. (2007) [Pubmed]
  5. Azacitidine. Issa, J.P., Kantarjian, H.M., Kirkpatrick, P. Nat. Rev. Drug. Discov (2005) [Pubmed]
  6. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. Issa, J.P., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., Kantarjian, H.M. J. Clin. Oncol. (2005) [Pubmed]
  7. Azacitidine. Issa, J.P., Kantarjian, H. Nat. Rev. Drug. Discov (2005) [Pubmed]
  8. Decitabine in chronic leukemias. Issa, J.P., Byrd, J.C. Semin. Hematol. (2005) [Pubmed]
  9. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Issa, J.P. Nature Clinical Practice. Oncology (2005) [Pubmed]
  10. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J., Kantarjian, H.M. Blood (2004) [Pubmed]
  11. CpG island methylator phenotype in cancer. Issa, J.P. Nat. Rev. Cancer (2004) [Pubmed]
  12. Age-related epigenetic changes and the immune system. Issa, J.P. Clin. Immunol. (2003) [Pubmed]
  13. Decitabine. Issa, J.P. Curr. Opin. Oncol (2003) [Pubmed]
  14. Epigenetic variation and human disease. Issa, J.P. J. Nutr. (2002) [Pubmed]
  15. Accelerated age-related CpG island methylation in ulcerative colitis. Issa, J.P., Ahuja, N., Toyota, M., Bronner, M.P., Brentnall, T.A. Cancer Res. (2001) [Pubmed]
WikiGenes - Universities